We presumed that high ATF1 expression confers resistance to PARP inhibitors in cancer cells with HRD because of the alteration of non-BRCA1 HR factors, such as BRCA2, in which sufficient ATF1 and intact BRCA1 could stimulate ATF1-mediated transactivation. The gene discussed is ATF1; the disease is cancer.